RZLT — Rezolute, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1509261 ·
Last close
$4.64
Market Cap
$448.79M
52W High
$11.46
52W Low
$1.07
ADV30
1,593,533
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -17,366,000 | -16,171,000 | 125,459,000 | 11,236,000 | 8,625,000 |
| Dec 2025 | 0 | — | -24,221,000 | -22,774,000 | 138,629,000 | 11,944,000 | 10,631,000 |
| Sep 2025 | 0 | — | -19,817,000 | -18,150,000 | 158,664,000 | 9,098,000 | 11,496,000 |
| Jun 2025 | 0 | — | -25,850,000 | -24,390,000 | 175,490,000 | 94,107,000 | 13,363,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-73,484,000
Investing CF
$-33,050,000
Financing CF
$103,174,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-09-27
Balance + Analyst (yfinance extras)
Retained Earnings
$-460,951,000
Inventory
—
Receivables
—
ST Investments
$109,032,000
EBIT TTM
$-87,254,000
Pretax Income TTM
$-81,485,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -79,894,000 | -74,412,000 | 175,490,000 | 13,363,000 | 162,127,000 | -69,075,000 |
| Jun 2024 | 0 | -70,423,000 | -68,459,000 | 132,737,000 | 11,734,000 | 121,003,000 | -57,368,000 |
| Jun 2023 | 0 | -55,990,000 | -51,787,000 | 123,721,000 | 7,549,000 | 116,172,000 | -44,481,000 |
| Jun 2022 | 0 | -41,612,000 | -41,060,000 | 152,420,000 | 2,949,000 | 149,471,000 | -39,616,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-81,485,000
OpCashFlow TTM
—
Assets (Latest)
$125,459,000
Forward EPS
$-0.63
Max Pain — expiry 2027-01-15
max pain strike: $2.50 · spot: $4.69 · call oi: 17,266 · put oi: 1,150
Expected Move to 2027-01-15:
±$2.95
(62.85%) —
implied range
$1.74 –
$7.64
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KMDA | KAMADA LTD | $448.70M | $7.78 | — |
| SPRY | ARS Pharmaceuticals, Inc. | $453.48M | $4.56 | — |
| IBO | IMPACT BIOMEDICAL INC. | $443.15M | $4.11 | — |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $442.01M | $8.61 | — |
| OVID | Ovid Therapeutics Inc. | $457.00M | $2.34 | — |
News headlines (Yahoo Finance, 1h cache)
Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’
2026-10-05 12:58 · Yahoo
Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment
2026-10-05 12:04 · Yahoo
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
2026-10-05 11:00 · Yahoo
Sector Update: Healthcare Stocks Softer Late Afternoon
2026-09-09 19:49 · Yahoo
Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint
2026-09-09 14:43 · Yahoo
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
2026-09-09 11:00 · Yahoo
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
2026-07-21 11:30 · Yahoo
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
2026-06-17 11:00 · Yahoo
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
2026-06-04 11:30 · Yahoo
Rezolute’s stock up on interim Phase III tumour HI data
2026-06-03 11:47 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.